Some features of beckman.com will be unavailable from 8:00 p.m. PDT Saturday, December 7 until 12:00 a.m. PDT, Sunday, December 8 for planned maintenance. During this time, you will not be able to log in to use account features such as online shopping, shopping lists and order tracking.
Please ensure your orders are processed prior to this maintenance period or contact Client Services for additional assistance.
CAR-T cells are not free from non-targeted and unintended effects. The common usage of viral vector systems for gene transfer carries a chance of insertional mutagenesis. CAR integration into more differentiated cells (as opposed to stem cells) can potentially limit this.1
Since very few antigens are tumor cell-exclusive, CAR antigen targeting can result in the targeting and elimination of healthy cells. This is most prominent when CAR-T cells are used to treat hematopoietic cancers (e.g., CD19 targeting will eliminate all CD19 B cells, resulting in B-cell aplasia), but can also manifest as “off organ” toxicities – where a highly expressed cancer cell antigen in one organ is also a key mediator of physiological function in a different organ.1
Finally, the rapid and sudden introduction of a large number of active and potent T cells has a dramatic effect on the extent and nature of host immune responses. Systemic inflammation- and cytokine storm-related toxicity has been observed post CAR-T cell administration.1
1. G. Dotti, et al., “Design and Development of Therapies using Chimeric Antigen Receptor-Expressing T cells,” Immunol Rev 257(1):10, 2014.
Oops. The page you wanted could not be found, so we brought you to something similar. If you still can't find what you want, try searching our site instead.